Examines the association of the therapeutic benefit of allogeneic bone marrow
transplantation with immune-mediated graft-versus-malignancy effect. Information on graft …

Donor lymphocyte infusion (DLI) is used after both myeloablative and non-myeloablative
stem-cell transplantation to treat and prevent relapse, to establish full donor chimerism, and …

We investigated the use of adoptively transferred donor-derived cytomegalovirus (CMV)
specific cytotoxic T lymphocytes (CTL) as immune reconstitution postallogeneic transplant in …

Donor lymphocyte infusion (DLI) was originally administered as a single, relatively large
dose of lymphocytes called a bulk dose regimen (BDR). It has since been suggested that the …

An analysis was performed of the response to treatment with donor lymphocyte infusions
(DLI) and the survival in 66 consecutive patients who relapsed after primary treatment by …

Data on the application of donor lymphocyte infusions (DLIs) following reduced-intensity
transplantation (RIT) remain limited. Persistence of host antigen-presenting cells might …

The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone
marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated …

The impact of donor lymphocyte infusion (DLI) initial cell dose on its outcome is known in
patients with chronic myeloid leukemia but limited in patients with other hematological …

This study retrospectively analyzed data from 446 patients given hematopoietic cell
transplants from HLA-matched related or unrelated donors after conditioning with 2 Gy total …

Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with
acute leukemia. Unfortunately, many patients relapse and die of their disease even after …